Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies
ConclusionsTwo doses of 20 µg and 40 µg ReCOV are safe and immunogenic against SARS-CoV-2 prototype. The cross-neutralizing activities against Omicron variants support ReCOV advance to late-stage clinical trials.Trial RegistrationPhase I study, clinicaltrials.gov NCT04818801; phase II study, clinicaltrials.gov NCT05084989.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research
More News: Clinical Trials | Covid Vaccine | COVID-19 | Headache | Infectious Diseases | Migraine | New Zealand Health | Pain | Philippines Health | SARS | Study | Vaccines